The lung cancer community is mourning the loss of Bonnie J. Addario, who passed away on August 25, 2025, at the age of 77. She leaves behind her beloved husband of over 40 years, Tony; her children Danielle, Jared, [...]
By Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation; Andrew Ciupek, PhD, Associate Director, Clinical Research; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research; Heather Law, MA, Associate Director, Lung Cancer Registry; Richard Erwin, Executive Director of the [...]
Recently, lung cancer professionals from across the globe gathered to connect and discuss developments impacting the lung cancer community at the International Association for the Study of Lung Cancer (IASLC)’s World Conference for Lung Cancer (WCLC) in San Diego, [...]
Researchers, oncologists, pulmonologists, thoracic surgeons, and patients convene at the World Conference on Lung Cancer (WCLC) each year to discuss developments impacting the lung cancer community. This year the International Association for the Study of Lung Cancer (IASLC)’s [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer You’ve likely started to see artificial intelligence (AI) being used more and more in your everyday life. While the benefits and challenges of using AI [...]
Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer With decades of research and advances in precision medicine, scientists continue to broaden the treatment standards and options for patients with non-small cell lung cancer (NSCLC). By [...]
Treatment for lung cancer has advanced considerably over the years and has been accelerating at an even faster rate this past decade. People diagnosed with lung cancer today have newer, more personalized treatment options that may include targeted therapies, [...]
GO2 for Lung Cancer is excited to announce that after airing our Lung Cancer Living Room monthly events only online for the past three years, we will be returning to in-person Living Room events from our San Carlos office [...]
Stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated in recent years by the genetic mutation, or biomarker. Patients received either chemotherapy, immunotherapy, a combination of the two, or a personalized targeted therapy depending on the [...]
For several years stage 4 adenocarcinoma non-small cell (aNSCLC) lung cancer treatment has been dictated by the genetic mutation, called biomarkers, of the patient. A patient’s treatment was seen as either chemotherapy, immunotherapy (or some sort of combination of [...]